Galapagos (GLPG)
(Delayed Data from NSDQ)
$30.16 USD
+0.86 (2.94%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $30.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Galapagos NV [GLPG]
Reports for Purchase
Showing records 1 - 20 ( 27 total )
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for GLPG 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Filgotinib CRL Puts High Risk Pipeline in Focus; Lowering to Neutral and Target Reduced to $123
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
2Q20 Update; Looking Beyond Filgotinib to Other Pipeline Readouts During 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
A Step Towards Potential Commercial Differentiation
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
A Stat-Sig Phase 3 Win; But Commercial Impact and MANTA Uncertainties Loom; Target Lowered to $270
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
SELECTION Phase 3 Readout a Couple of Weeks out Plus Our Cheat Sheet on Historic UC Phase 3 Outcomes
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Staying the Course for Now and Raising Target to $302
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Bringing a Wallet to a Hammer and Sickle Fight, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Consolidation Post Gilead Transaction; Model Updates Post 3Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
2H19 Value Drivers Within Our Coverage Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Thoughts Post C-Suite Investor Meetings
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Company: Galapagos NV
Industry: Medical - Biomedical and Genetics
Gilead Opts for Decentralized R-D Model With a $5.1B Collaboration; Target to $205 From $150
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D